Judge’s abortion pill ruling in Texas is “extraordinary and unprecedented”, the U.S. Justice Department said in an appeal to the ruling. Justice Department said that the ruling invalidates the U.S. FDA‘s approval of mifepristone in 2020, U.S. News reported. It can be recalled that mifepristone is the first of two drugs taken during a medical abortion.
Abortion Pill Ruling in Texas
Justice Department said in its statement that if the abortion pill ruling will take effect, the court’s order would frustrate Food and Drug Administration’s scientific judgment and can potentially harm women, especially those for whom mifepristone is a medical necessity.
Within 20 minutes of the order of a Texas federal judge, where Democrats had sued, a federal judge in Washington issued a ruling directing the FDA to make no changes that would restrict access to the drug in 17 states. U.S. District Judge, Matthew Kacsmaryk said the order would not take effect for seven days. The U.S. Justice Department asked for further clarification on this ruling.
Executives in the Pharmaceutical industry signed a letter on Monday warning about the possible impact of the order. They also weighed in on the ruling. They said that if federal courts can overturn approvals on drugs without considering scientific facts and evidence, any medicines or drugs are at risk the same as mifepristone.
Remarkably, the Alliance Defending Freedom filed a lawsuit, they alleged that the FDA should not approve mifepristone because it did not adequately review its risks.
READ ALSO: Chuck Schumer Warns of Chaos As Texas Judge Halts FDA Approval Of Abortion Pill
Is Mifepristone Going to Be Banned?
For more than 20 years, Mifepristone has been used in the United States together with misoprostol. Mifepristone banning could possibly result in confusion for many providers about whether they will be switching to prescribing just misoprostol for medication abortions or performing any legal surgical abortions
Overall, Judge’s abortion pill ruling in Texas faces criticism from the U.S. Justice Department. Executives in the Pharmaceutical industry also express their concerns about the possible impact of the order.
